In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...
ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ...
Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...
Zacks Investment Research on MSN
ADCT stock plunges on safety concerns despite positive lymphoma data
ADC Therapeutics ADCT shares plunged 53.4% in after-hours trading on Wednesday despite the company reporting positive ...
OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...
10h
ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA Data - Has The Bull Case Changed?
In early June 2026, ADC Therapeutics reported topline Phase 3 LOTIS-5 data showing ZYNLONTA plus rituximab improved progression-free survival and response depth versus R-GemOx in relapsed or ...
Offering a Sense of Hope for Diffuse Large B-cell Lymphoma The Evolving Role of Bispecific Antibodies in Diffuse Large B-cell Lymphoma ...
Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling often in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results